RecruitingPhase 2NCT05723588

Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD


Sponsor

VA Office of Research and Development

Enrollment

50 participants

Start Date

Oct 31, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Tobacco use is the number one preventable cause of the death in the United States, and is high among US Veterans, and those who have experienced trauma are more likely to smoke. Despite the efficacy of current evidence-based treatments for smoking cessation, there is a critical need for alternative treatments. This project seeks to evaluate the feasibility and effectiveness of a smoking cessation treatment for Veterans with posttraumatic stress disorder (PTSD) who smoke. The treatment combines smoking cessation counseling, nicotine replacement therapy (e.g., nicotine gum), and repetitive transcranial magnetic stimulation (rTMS). rTMS is a noninvasive brain stimulation treatment that has been cleared by the Food and Drug Administration for smoking cessation in adults.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria9

  • Is a US Veteran
  • Meets DSM-5 criteria for tobacco use disorder
  • Is between the ages of 18 and 75
  • Smokes an average of 10 cigarettes per day for the past 6 months, with carbon monoxide (CO) level \> 6 ppm
  • Is willing to attempt smoking cessation
  • Meets DSM-5 criteria for current PTSD diagnosis
  • Speaks, reads and writes English
  • Is willing to sign a Duke consent for those portions of the study that occur at Duke
  • Has been stable on psychotropic medications for at least three months

Exclusion Criteria16

  • Has had a substance use disorder other than tobacco in the preceding 3 months
  • Has a history of myocardial infarction in the past 6 months or has another contraindication to NRT
  • Has a contraindication to TMS or MRI
  • Personal or family history of a seizures or epilepsy
  • History of neurological condition that increases the risk of seizures including stroke or transient ischemic attack, cerebral aneurysm, or severe traumatic brain injury from a penetrating head injury, loss of consciousness \> 20 minutes at time of traumatic injury, requiring an anticonvulsant medication for seizures, and/or found to have encephalomalacia on baseline MRI
  • Structural brain lesion, or prior brain surgery
  • Ferromagnetic metal in head (including shrapnel)
  • Implanted devices that may be affected by MRI or TMS (pacemaker, medication pump, cochlear implant, implanted deep brain stimulator)
  • Is pregnant (to be determined at Duke)
  • Is unable to complete study procedures
  • Is currently prescribed bupropion and/or varenicline
  • Uses other forms of nicotine such as cigars, pipes, chewing tobacco, or vaping
  • Is unable to provide informed consent due to a major neurocognitive disorder or other reason
  • Meets criteria for a primary psychotic disorder or current manic episode
  • Is currently imprisoned or psychiatrically hospitalized
  • Has previously received rTMS

Interventions

DEVICEactive repetitive transcranial magnetic stimulation

Active rTMS is a non-invasive brain stimulation intervention that is FDA cleared as a treatment for smoking cessation in adults.

DEVICEsham repetitive transcranial magnetic stimulation

Sham rTMS involves no brain stimulation, but appears to the participant and provider to be active rTMS.

BEHAVIORALcognitive behavioral therapy for smoking cessation

All participants will receive five sessions of cognitive behavioral therapy (CBT) for smoking cessation.

DRUGnicotine replacement therapy

All participants will receive nicotine replacement therapy in for the form of 21 mg, 14 mg, and/or 7 mg nicotine patches (based on smoking quantity) and a "rescue" method such as nicotine lozenge or nicotine gum.


Locations(1)

Durham VA Medical Center, Durham, NC

Durham, North Carolina, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05723588


Related Trials